Leave a comment

EU-Japan Cluster Matchmaking Even at BioEurope Report

The “EU‐Japan Cluster Matchmaking Event” was held at BIO‐Europe in Frankfurt, Germany, on November 3rd, 2014. Leading Japanese health care cluster representatives and their European counterparts met to build first bridges between their organisations in order to path the way for potential collaborations – and long-term to support SMEs to find business partners.

EU-Japan Foto Four key regions plus The Japan Bioindustry Association (JBA) outlined the vast array of opportunities that the Japanese pharma and health market offers to Europe. 30 attendees took also the advantage of exchanging business contacts and to meet people offering to help with building valuable connections in the otherwise difficult to approach Japanese market.

It is planned to follow up with a 2nd EU-Japan Cluster Matchmaking Event at BIO-Europe 2015 in Munich.

Report – EU-Japan matchmaking event

Leave a comment

EU-Japan Cluster Matchmaking Even at BioEurope – 3rd November 2014

The EU‐Japan Cluster Matchmaking Event – financially supported by the European Commission ( – is taking place at Bio Europe in Frankfurt (Germany) on November, 3rd. It provides the perfect opportunity to gain an overview of the strengths of the Japanese life sciences landscapes and clusters in the health care sector.

Speakers from four leading Japanese life science clusters and from Japan Bioindustry Association (JBA) will present the vast array of opportunities that the Japanese pharma and health market offers to European companies.

If you work for a European life science cluster or if you are a manager of a company that targets the Japanese market, do not miss the opportunity to establish valuable contacts at this event. It creates the basis for cluster cooperations, R&D projects, licensing opportunities, attracting joint partnerships, developing small scale, high value manufacturing projects, developing commercial activities and establishing your presence in the Japanese market by using soft landing facilities.

Agenda – EU-Japan matchmaking event

Your participation is free and no registration is required. For more information, please contact us:


USA Mission report

BioXclusters partners, along with some European SMEs, went to Boston (Massachusetts) last October 2013. Read the report we have produced with the description of the visits and information about the life sciences market.

The objective of the mission in Boston was to discover and detect key entry points of the biotech and medtech market in the USA and collaboration opportunities with the different organizations visited. The USA represents a key market in life sciences, and notably for Personalized Healthcare. With a life sciences sector weighting $61 billion and counting about 1.455 companies, among which 300 quoted in stock exchange, the USA is without any doubt the top-leading economy on this market.

The life sciences is indeed one of the most dynamic sector of the American economy were not less than $30 billion were invested for R&D in 2010. The American life sciences market alone accounts for 70% of the world turnover and for 15 % of the total sales of the biotechnologies market. Read more

1 Comment

Internationalisation in life sciences: the role of clusters

Internationalisation, especially in China, is considered sometimes as an issue by SMEs and clusters. In life science it is not an option. The activity of the sector cannot be constricted to national borders.

The market is global and the competition is global. SMEs are not always sure about how to face other markets that can offer big opportunities but also present big challenges.  In such scenario which is the role of clusters?

Internationalisation in Life Sciences – the whole text by Fabrizio Conicella

1 Comment

China Mission report

BioXclusters partners, along with some European SMEs, went to Shanghai last May 2013. Read the report we have produced with the description of the visits and information about the life sciences market.

The objective of the mission in China was to discover and detect key entry points of the life science market in this country. The Chinese market offers huge opportunities in the health care sector: it has undergone yearly growth rates above 20% during the last 10 years. However, cultural gap and a difficult IP regulation, among others, are to be taken into account when establishing commercial and technological relations with local Chinese partners. The question that the bioXclusters partners tried to answer through this mission was how to help the European SMEs penetrate this very fast growing market and keep a long-lasting position on it. Read more

1 Comment

bioXclusters partners take part in the Brazil mission headed by the European Commission

From September 10 to 12 2013, the European Commission travelled to Brazil with a selection of 9 life sciences European clusters alongside 4 SMEs. The mission had the objective of fostering bilateral exchanges at different levels between European and Brazilian partners. For that purpose, the mission was organised around the BioPartnering Latin America event.

Photo by Paulo Valle

Photo by Paulo Valle

bioXclusters partners participated in this mission as special guests selected to advise the organizers on how to face this market, based on their former experience of last year’s mission.

During the BPL event, European and Brazilian clusters had the opportunity to exchange presentations, information and business models.

Brazil continues to move up in the ranking of fast-growing countries. Being today the world’s sixth biggest economy, Brazil undoubtedly offers opportunities at different levels, even though we should not forget that it is still a protective country in many aspects. However, despite these barriers, Brazil clearly offers growth and business possibilities. Its sustainable growth during the past decade has lifted more than 40 million people out of poverty and into the middle class.

The life sciences sector can offer a wide range of opportunities for European organizations.

The health sector is one of the most important booming markets of Brazil, the most populous country in South America with nearly 200 million inhabitants. Emphasis in the domain of red biotechnology is placed on vaccine production, diagnostics and biomedical services. The country also offers good framework conditions for clinical trials.

As we can read in a recent report, “There have been notable advances in Brazil’s public health in the last 10 years, especially in infant and maternal health. Life expectancy has been rising constantly, as fertility and infant mortality rates have fallen. It seems that all the health-related Millennium Development Goals are going to be met. The once most unequal country in the world has taken effective steps to address poverty and extend the social security system. It is not only the health sector but also underlying social determinants that have been improved, and this can be seen in better health outcomes. However, infectious diseases like dengue, tuberculosis and HIV continue to play a significant role. There are also growing rates of lifestyle diseases such as high blood pressure, diabetes”.

Human resources are “one of the most limiting factors. There are not enough doctors willing to fill the new and modern clinics. The role of the health professional within the PSF demands a lot of ethical and social dedication. With their background and understanding of the medical profession, many Brazilian physicians are not attracted and not prepared to work in marginalized neighbourhoods overburdened with social problems.” [1]

As already said in our first report, opportunities are there.


Get every new post delivered to your Inbox.

Join 29 other followers